Diagnostics company Genetic Technologies (ASX:GTG) has been granted a trading halt by the ASX pending a capital raising, with its shares placed in pre-open.
The company is focussed on commercialising genetic testing, non-coding DNA and product patenting.
This its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets.
The halt will remain in place until the opening of trade on Thursday 11th September 2014, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.